Free Trial
NASDAQ:INTS

Intensity Therapeutics Q1 2026 Earnings Results & Report

Intensity Therapeutics logo
$3.06 -0.02 (-0.49%)
As of 03:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Intensity Therapeutics beat analyst earnings expectations in its Q1 2026 results, released May 7, 2026. The company reported EPS of -$0.96 versus the -$1.0850 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Intensity Therapeutics EPS Results

Actual EPS
-$0.96
Consensus EPS
-$1.0850
Beat/Miss
Beat by +$0.1250
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 7 quarters

Intensity Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Intensity Therapeutics Q1 2026 Earnings FAQ

Intensity Therapeutics (NASDAQ:INTS) reported earnings of -$0.96 per share for Q1 2026, beating the consensus estimate of -$1.0850. The report was announced on Thursday, May 7, 2026.

Intensity Therapeutics Earnings Headlines

What is HC Wainwright's Estimate for INTS FY2026 Earnings?
Brookline Capital Markets Forecasts INTS FY2026 Earnings
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
Intensity (INTS) Q3 2026 Earnings Call Transcript
See More Intensity Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Intensity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Intensity Therapeutics and other key companies, straight to your email.

About Intensity Therapeutics

Intensity Therapeutics (NASDAQ:INTS), Inc. is a clinical-stage biotechnology company developing treatments for solid tumors. Its approach centers on delivering cancer-killing agents directly into tumors, with the goal of treating the tumor while also stimulating an immune response.

The company’s lead investigational product, INT230-6, combines the chemotherapy agents cisplatin and vinblastine sulfate with a proprietary molecule intended to help the drugs spread through tumor tissue and enter cancer cells. Intensity has evaluated INT230-6 in clinical studies as a treatment for solid tumors.

Founded in 2012, Intensity Therapeutics is led by founder and Chief Executive Officer Lewis Barger. Its work is focused on developing and clinically testing its intratumoral treatment platform.

View Intensity Therapeutics Profile